A pivotal trial of MT-3724 in pateints with non-Hodgkin's Lymphoma (NHL)

Trial Profile

A pivotal trial of MT-3724 in pateints with non-Hodgkin's Lymphoma (NHL)

Planning
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs MT 3724 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Mar 2017 According to a Molecular Templates media release, the company expects to initiate this trial before the end of 2017.
    • 25 Mar 2017 New trial record
    • 17 Mar 2017 According to a Threshold Pharmaceuticals media release, Threshold Pharmaceuticals and Molecular Templates Agree to Combine and Combined company will be capitalized to support advancement of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top